IO Biotech ApS is a clinical stage company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the micro-environment in addition to direct targeting of cancer cells.